Skip to main content
. Author manuscript; available in PMC: 2020 Mar 2.
Published in final edited form as: Chem Commun (Camb). 2018 Jun 19;54(54):7479–7482. doi: 10.1039/c8cc04251a

Fig. 1.

Fig. 1

(a) Structures of gefitinib and the newly designed platinum–TKI hybrid agents 1–4 (tmeda stands for N,N,N’,N’-tetramethylethylenediamine), and (b) proposed mechanism of the hybrid agents involving reversible, high-affinity recognition of the ATP-binding pocket and subsequent irreversible cysteine modification.